Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates

Gynecologic Oncology

Volumn 137, Issue 3, 2015, Pages 430-435

  Liao, John B ^a   Yip, Yuen Yee ^a   Swisher, Elizabeth M ^a   Agnew, Kathy ^a   Hellstrom, Karl Erik ^a   Hellstrom, Ingegerd ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ELISA; HE4; LMP; Ovarian cancer; Urine

Indexed keywords

CA 125 ANTIGEN; HE4 PROTEIN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WFDC2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GYNECOLOGIC DISEASE; HUMAN; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; URINALYSIS; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; URINE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEINS;

EID: 84930040109     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.03.044     Document Type: Article

References (24)

1. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum. Reprod. 4 1989 1 12
2. J.S. Berek, and R.C. Bast Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection Cancer 76 1995 2092 2096
3. T. Maggino, A. Gadducci, V. D'Addario, S. Pecorelli, A. Lissoni, M. Stella, C. Romagnolo, M. Federghini, S. Zucca, and D. Trio Prospective multicenter study on CA 125 in postmenopausal pelvic masses Gynecol. Oncol. 54 1994 117 123
4. C. Kirchoff, I. Habben, R. Ivell, and N. Krull A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitor Biol. Reprod. 45 1991 350 357
5. M. Schummer, W. Ng, R. Bumgarner, P. Nelson, B. Schummer, D. Bednarski, L. Hassell, R. Baldwin, B. Karlan, and L. Hood Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas Gene 238 1999 375 385
6. K. Wang, L. Gan, E. Jeffery, M. Gayle, A.M. Gown, M. Skelly, P.S. Nelson, W.V. Ng, M. Schummer, L. Hood, and J. Mulligan Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray Gene 229 1999 101 108
7. K. Ono, T. Tanaka, T. Tsunoda, O. Kitahara, C. Kihara, A. Okamoto, K. Ochiai, T. Takagi, and Y. Nakamura Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res. 60 2000 5007 5011
8. A.M. Dandekar, E.A. Robinson, E. Appellla, and P.K. Quasba Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor Proc. Natl. Acad. Sci. 79 1982 3987 3991
9. R. Heinzel, H. Appelhans, G. Gassen, U. Seemuler, W. Machleidt, H. Fritz, and G. Steffens Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus Eur. J. Biochem. 160 1986 61 67
10. O. Wiedow, J.M. Schroder, H. Gregory, J.A. Young, and E. Christophers Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence J. Biol. Chem. 265 1990 14791 14795
11. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban, and K.E. Hellstrom The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res. 63 2003 3695 3700
12. R.G. Moore, A.K. McMeekin DS, P. DiSilvestro, M.C. Miller, W.J. Allard, W. Gajewski, R. Kurman, R.C.J. Bast, and S.J. Skates A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 112 2009 40 46
13. I. Hellstrom, and K.E. Hellstrom Two new biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma Expert. Opin. Med. Diagn. 5 2011 227 240
14. ACOG Committee Opinion: Number 678 Avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test results. Committee on Gynecologic Practice, ACOG Obstet. Gynecol. 100 5 Pt 1 2002 1057 1059
15. B. Ye, S. Skates, S.C. Mok, N. Horick, H.F. Rosenberg, and A. Vitonis Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine Clin. Cancer Res. 12 2006 432 441
16. D. Badgwell, Z. Lu, L. Cole, H. Fritsche, E.N. Atkinson, E. Somers, J. Allard, R.G. Moore, K.H. Lu, and J.R.C. Bast Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment Gynecol. Oncol. 106 2008 490 497
17. I. Hellstrom, and K.E. Hellstrom SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other Adv. Exp. Med. Biol. 622 2008 15 21
18. N.S. Anderson, Y. Bermudez, D. Badgwell, R. Chen, S.V. Nicosia, J.R.C. Bast, and P.A. Kruk Urinary levels of Bcl-2 are elevated in ovarian cancer patients Gynecol. Oncol. 112 2009 60 67
19. I. Hellstrom, P.J. Heagerty, E.M. Swisher, P. Liu, J. Jaffar, K. Agnew, and K.E. Hellstrom Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms Cancer Lett. 296 2010 43 48
20. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, T. Vercy, M. Steinhoff, G. Messerlian, P. DiSilvestro, C.O. Granai, and R.C.J. Bast The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol. Oncol. 108 2008 402 408
21. B.M. Nolen, and A.E. Lokshin Biomarker testing for ovarian cancer: clinical utility of multiplex assays Mol. Diagn. Ther. 17 2013 139 146
22. E.L. Braicu, R. Chekerov, R. Richter, C. Pop, M. Nassir, H. Loefgren, F. Stamatian, M.Z. Muallem, Fotopoulou C. Hall, J. Sehouli, and K. Pietzner HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse Ann. Surg. Oncol. 21 3 2014 955 962
23. E.L. Braicu, C. Fotopoulou, T. Van Gorp, R. Richter, R. Chekerov, C. Hall, H. Butz, D.C. Castillo-Tong, S. Mahner, R. Zeillinger, N. Concin, I. Vergote, and J. Sehouli Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study Gynecol. Oncol. 128 2 2013 245 251
24. R. Angioli, S. Capriglione, A. Aloisi, F. Guzzo, D. Luvero, A. Miranda, P. Damiani, R. Montera, C. Terravona, and F. Plotti Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumor Biol. 35 7 2014 7009 7015